Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nimotuzumab Combined With Neoadjuvant Chemotherapy (TPF) in the Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT05351762 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT05351762
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05351762 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nimotuzumab Combined With Neoadjuvant Chemotherapy (TPF) in the Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Lead sponsor
Xijing Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
July 1, 2022
Completion date
July 30, 2024
Enrollment
55 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma